Caplin Point Laboratories Q1 FY27 earnings call

Caplin Point Laboratories reported a robust Q1 FY27, with overall revenue growing by 20% year-on-year. This growth was supported by an 18% increase in the conventional market and a significant 26% surge in the US market. The US subsidiary's revenue notably increased threefold from INR 14.4 crores in the previous year to INR 43.7 crores this quarter. Gross margin was maintained at 59.8%, and improved operating efficiency led to an EBITDA margin increase from 37.7% to 38.4%. PAT grew by 19% to INR 179 crores, with PBT reaching INR 225.2 crores, up 22.1%.

The company is aggressively expanding its manufacturing capacity, with plans to increase sterile lines from the current 6 to 13 by next year, and potentially 17 by 2029. This includes commissioning Line 7 within 6-7 months and adding five more lines from the new Phase 3 facility next year. This expansion is critical to address the current capacity constraints, as the company is 'booked out till almost February of next year.' All capacity expansion initiatives are funded entirely through internal cash flow, without reliance on external bank loans.

Caplin Point is undertaking a comprehensive digitalization drive across its facilities. The CSL facility is already 80-90% digitized and is expected to become paperless within the next 6 months. This initiative involves implementing advanced systems like LIMS, QC, Micro systems, eLog, eBMR, and eBPR. Furthermore, the company is introducing video masters for visual learning and plans to integrate AI cameras and digital twins within 1-2 years to enhance institutional knowledge, enable remote monitoring, and ensure transparency in operations.

The company is strategically expanding its addressable markets beyond smaller Latin American geographies into larger ones, focusing on oncology, branded generics, and new markets such as Chile and Mexico. A key initiative is the planned acquisition of a distribution company in Mexico, with 3-4 targets identified, to gain deeper insights into product selection and customer identification. The product pipeline includes over 40 products in pre-filled syringes and ophthalmic suspensions, and new facilities will enable entry into niche areas like blow-fill-seal and inhalation products.

Caplin Point maintains a strong financial position, with free cash reserves of INR 1,502 crores and total liquid assets of INR 2,875 crores as of June 2026, representing a 30% increase year-on-year. Cash and cash equivalents increased by INR 265 crores from June 2025 to June 2026. While prioritizing capital protection, management is open to exploring investments in index funds for better yield, considering an initial allocation of INR 200-300 crores. All capex for expansion is self-funded, ensuring financial flexibility for future growth and potential inorganic opportunities.

Cash flow from operations for Q1 FY27 was INR 95 crores, which was lower than anticipated due to strategic inventory build-up. The company consciously increased warehouse stock by INR 76 crores, from INR 429 crores in March to INR 505 crores, equivalent to 2.5x sales, to mitigate potential supply chain disruption^🌐s. Additionally, RM and PM inventory increased by INR 15 crores to shield against price increases. Receivables also rose by INR 46 crores due to government supplies, expected to be collected by Q3 FY27, indicating an expected improvement in CFO from Q2 onwards.